NIH Funding Slowdown Disrupts Research Labs and Early-Career Scientists
NIH has obligated only 15% of its $38 billion budget halfway through the fiscal year, causing universities to cut PhD admissions and implement hiring freezes. Early-career scientists face declining grant success rates despite increased applications. Congress recently reversed proposed 40% NIH budget cuts that had threatened research facility construction.
The National Institutes of Health is experiencing a significant slowdown in distributing research funds, committing only about 15 percent of its estimated $38 billion budget halfway through the federal fiscal year. This delay, stemming from last year's prolonged government shutdown, has forced universities to reduce Ph.D. admissions, implement hiring freezes, and in some cases lay off staff, while early-career scientists face dwindling grant success rates.
At the halfway mark of the fiscal year, NIH had obligated just $5.8 billion, compared to approximately $9 billion at the same point in the previous cycle. The slowdown began with a seven-week government shutdown that stalled grant-making machinery, and despite resuming activity in December, the agency obligated only $1.2 billion that month followed by $2 billion across January and February. This pace falls short of historical trends, with the first half of this fiscal year showing markedly lower funding activity than any of the past five years.
The funding gap is having tangible consequences across the research ecosystem. NIH has issued just 1,187 new grants since October, representing a 63 percent decrease from the five-year average at this stage. Universities are responding by reducing life sciences Ph.D. admissions, offering conditional acceptances, and implementing hiring freezes. Research universities operate on long timelines where faculty hiring, student admissions, and lab investments are tightly interwoven with expected grant flows, making unpredictability particularly damaging.
Early-career researchers are experiencing the sharpest impact. Applications for R01-equivalent grants, often the gateway to independent research careers, rose last year while awards fell. In 2024, about a quarter of applicants secured funding, but that share dropped noticeably in 2025 despite a larger applicant pool. These scientists, typically within a decade of completing their training and building their first labs, face professional setbacks that could push them out of academia entirely.
The current slowdown follows a pattern from last year when NIH pushed more than half of its annual research funding into the final three months of the fiscal year, leaning heavily on multiyear grants at the expense of new awards. The Association of American Medical Colleges has emphasized that predictable funding is essential not only for scientific progress but for ensuring that public investment delivers meaningful returns.
Meanwhile, Congress recently reversed proposed steep cuts to NIH funding that would have reduced the agency's budget by 40 percent. The new $48.7 billion budget is larger than last year's, though essentially flat when adjusted for inflation. The reversal preserves stability for a major funding source that drives lab leasing and supports the academic heart of major biotech clusters.
The proposed cuts would have reduced indirect costs—facilities and administration funding—from $9 billion to $5 billion, impacting states like Massachusetts, California and North Carolina that are hubs of the biotech industry. Universities had already begun freezing plans for academic medical centers dependent on federal research dollars, with the University of North Carolina pausing a $218 million development and the University of California, San Diego delaying construction of key research buildings.
The life sciences lab real estate sector, while relieved by the funding restoration, continues to face challenges including high vacancy rates—33 percent in the Bay Area and 28 percent in Boston and San Diego—and uncertainty over drug approval timelines. The funding stability comes amid broader market challenges, with Alexandria Real Estate Equities posting a $1 billion loss during the fourth quarter of 2025 and predicting a year or more of difficult leasing conditions.